Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.325    0.075 (6.00%)
Bid:
1.25
Ask:
1.40
Spread: 0.15 (12.00%)
Market Cap: £21.27m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

18 Jul 2019 07:00

RNS Number : 9066F
Genedrive PLC
18 July 2019
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 51,250 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at an average price of 19p per share.

 

Following these purchases, Dr Gilham is interested in 317,674 Ordinary Shares, 0.93% of the issued share capital of the Company.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Ian Gilham

 

 

2.

Reason for the notification

a.

Position/status

Non-Executive Chairman

a.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

genedrive plc

b.

LEI

213800ZYODIRZ87Y4K14

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

 

Price(s)

Volume(s)

19p

51,250

 

d.

Aggregated information

· Aggregated volume

· Price

 

 

N/A

 

e.

Date of the transaction

2019-07-17; UTC time

f.

Place of the transaction

London Stock Exchange, AIM

 

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO

 

Matthew Fowler: CFO

 

Peel Hunt LLP

+44 (0)207 418 8900

James Steel

 

Oliver Jackson

 

 

Stanford Capital Partners Limited

 

+44 (0)20 3815 8880

 

Patrick Claridge / John Howes

 

 

 

Walbrook PR Ltd (Media Relations & Investor Relations)

 

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAEXXFSSNEAF
Date   Source Headline
10th Sep 20212:01 pmRNSProposed Placing and Open Offer
31st Aug 20217:00 amRNSNew Genedrive system readied for AIHL launch
1st Jul 20217:00 amRNSGenedrive COVID-19 Point of Care device update
25th Jun 20214:40 pmRNSSecond Price Monitoring Extn
25th Jun 20214:35 pmRNSPrice Monitoring Extension
25th Jun 20211:17 pmRNSGenedrive confirms receipt of India Import License
25th Jun 202111:05 amRNSSecond Price Monitoring Extn
25th Jun 202111:00 amRNSPrice Monitoring Extension
22nd Jun 202111:05 amRNSSecond Price Monitoring Extn
22nd Jun 202111:00 amRNSPrice Monitoring Extension
28th May 20216:00 pmRNSBlock listing Interim Review
28th May 20214:40 pmRNSSecond Price Monitoring Extn
28th May 20214:35 pmRNSPrice Monitoring Extension
6th May 20212:05 pmRNSSecond Price Monitoring Extn
6th May 20212:00 pmRNSPrice Monitoring Extension
30th Apr 20217:00 amRNSCOVID-19 PCR test approved by Indian regulator
23rd Apr 20217:00 amRNSExcellent performance data for Genedrive® HCV test
19th Apr 20217:00 amRNSPHE National Framework Agreement
1st Apr 20217:00 amRNSTotal Voting Rights
31st Mar 202111:05 amRNSSecond Price Monitoring Extn
31st Mar 202111:00 amRNSPrice Monitoring Extension
25th Mar 20217:00 amRNSHalf-year Report
9th Mar 20217:00 amRNSDistribution agreement
3rd Mar 20217:00 amRNSAntibiotic Induced Hearing Loss update
1st Mar 20214:41 pmRNSSecond Price Monitoring Extn
1st Mar 20214:35 pmRNSPrice Monitoring Extension
1st Mar 20217:00 amRNSInvestor Presentation
1st Mar 20217:00 amRNSTotal Voting Rights
17th Feb 20217:00 amRNSFirst US shipments of Genedrive® 96 SARS-CoV-2 Kit
12th Feb 20212:10 pmRNSHolding(s) in Company
10th Feb 20219:05 amRNSSecond Price Monitoring Extn
10th Feb 20219:00 amRNSPrice Monitoring Extension
9th Feb 20212:28 pmRNSHolding(s) in Company
8th Feb 20213:30 pmRNSHolding(s) in Company
8th Feb 202112:51 pmRNSHolding(s) in Company
8th Feb 202111:05 amRNSSecond Price Monitoring Extn
8th Feb 202111:00 amRNSPrice Monitoring Extension
2nd Feb 20212:05 pmRNSHolding(s) in Company
2nd Feb 20219:05 amRNSSecond Price Monitoring Extn
2nd Feb 20219:00 amRNSPrice Monitoring Extension
1st Feb 20211:22 pmRNSHolding(s) in Company
1st Feb 20219:05 amRNSSecond Price Monitoring Extn
1st Feb 20219:00 amRNSPrice Monitoring Extension
1st Feb 20217:00 amRNSTotal Voting Rights
29th Jan 20219:05 amRNSSecond Price Monitoring Extn
29th Jan 20219:00 amRNSPrice Monitoring Extension
28th Jan 20219:05 amRNSSecond Price Monitoring Extn
28th Jan 20219:00 amRNSPrice Monitoring Extension
28th Jan 20217:00 amRNSDistribution agreement with Beckman Coulter
25th Jan 202111:35 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.